

News Release

September 11, 2023

EA Pharma Co., Ltd.
TransThera Sciences (Nanjing), Inc.

TransThera and EA Pharma Announce Strategic Research Collaboration Focused on Novel Therapies for Inflammatory Gastrointestinal Diseases

EA Pharma Co., Ltd. (President, Hidenori Yabune; Headquarters, Chuo-ku, Tokyo, Japan, "EA Pharma") and TransThera Sciences (Nanjing), Inc. (Chief Executive Officer, Funder Frank Wu, Headquarter Jiangbei New Area, Nanjing, China, "TransThera") jointly announced to enter into a strategic research collaboration agreement to co-develop innovative therapeutics for novel targets in inflammatory diseases of the gastrointestinal ("GI") system and liver.

Under the agreement, EA Pharma and TransThera will jointly dedicate research resources to the discovery and development of potential clinical candidates. The two companies will establish a joint steering committee to coordinate all scientific matters of the collaboration.

"We are thrilled to announce the strategic research collaboration with TransThera to explore new drugs for GI and liver disease field." said Masafumi Minomura, Managing Director of R&D at EA Pharma, "Based on our original and unique drug discovery platform, we are excited to embark on a path for innovation together with innovative and dynamic TransThera with expertise in immunology, and through this collaboration we firmly believe that we can paint a bright picture of developing new therapies for GI and liver disease patients."

"This is an exciting opportunity for TransThera to work with EA Pharma as a global partner who shares our commitment to bringing transformative therapies to patients with highly unmet medical need." said Dr. Frank Wu, Founder and CEO of TransThera. "Immunology is a key area of focus for TransThera. We have a deep understanding of the complex biology of inflammatory diseases and an effective "ACE" (an acronym of Adaptive, Comprehensive and Expandable) platform for the discovery and optimization of novel small molecular medicines. Leveraging the strength of both companies in the drug innovation, we hold a strong belief that this collaboration will expedite the discovery process of novel therapies for patients."

Media Inquiries	
EA Pharma Co., Ltd. Corporate Communication Dept. TEL: +81(0)80-4176-5206	TransThera Sciences (Nanjing), Inc.. Rep in Japan (Kawamoto) TEL: 090-5659-8134

About EA Pharma

EA Pharma, established by the Eisai Group's gastrointestinal disease business and Ajinomoto Group's gastrointestinal disease business with amino acid technologies at its core integrated, is a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma is focused on the discovery and clinical development of treatments for inflammatory bowel disease (IBD) and a wide range of other gastrointestinal diseases, and on providing solutions to unmet clinical needs.

For more information, please visit EA Pharma Co., Ltd.

About TransThera

TransThera Sciences (Nanjing), Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via the internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, inflammatory, and cardiovascular diseases.

For more information, please visit www.transthera.com

Forward-looking statements

This Website contains forward-looking statements that involve risks, uncertainties, and assumptions. If risks or uncertainties ever materialize or the assumptions prove incorrect, our actual results may differ from those expressed or implied by such forward-looking statements. All statements other than statements of historical facts could be deemed forward-looking, including, but not limited to, any statement of the plans, strategies, and objectives of management for future operations, including but not limited to our clinical development and commercialization plans; any projections of financial information; any statements about historical results that may suggest trends for our business; any statements of expectation or belief regarding future events, potential markets or market size, technology developments, our product pipeline, clinical data, results or practices or the implications thereof, enforceability of our intellectual property rights, competitive strengths or our position within the industry; and any statements of assumptions underlying any of the items mentioned.